📰 Fixed Dose Combination News
Fixed Dose Combination News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Fixed Dose Combination. Real-time updates on events, politics, business and more.
January 12, 2024
In 2012, a parliamentary standing committee of the health ministry had observed in its report that some of the state licensing authorities issued manufacturing licences for a large number of FDCs without prior clearance from the central drug authority, resulting in the availability of several FDCs which were not tested for safety and efficacy.
January 5, 2024
Hawaiian Eye and Retina 2024 meetings will take place from January 13 to 19 at the Grand Wailea Maui, 3850 Wailea Alanui Drive, Wailea, HI.
January 4, 2024
The Centre banned the sale of Deanxit, a contested psychiatric drug approved without clinical data. But 10 years on, it continues to be sold by other companies.
December 31, 2023
Ga-Rankuwa – About 180 000 HIV positive patients are expected to start on the
December 21, 2023
Pharma firms manufacturing GlaxoSmithKline’s T-Minic Oral Drops, Glenmark’s Ascoril Flu Syrup, and IPCA Laboratories’ Solvin Cold Syrup, among others, have been asked by the regulator to insert a ‘warning’. - Govt Bans Common Cold And Flu Syrups For Kids Below 4 Yrs, Asks Pharma Companies To Insert Warnings | Check List
December 21, 2023
India's drug regulator has prohibited the use of a popular anti-cold medicine cocktail for children under the age of four. The drug regulator advised
December 20, 2023
The the Subject Expert Committee of the Central Drugs Standard Control Organisation recommended a precautionary measure, suggesting that the FDC should not be administered to children below 4 years
November 3, 2023
/PRNewswire/ -- The "Diagnostics and Therapeutics for HIV: Global Markets" report has been added to ResearchAndMarkets.coms offering. The global diagnostics...
September 5, 2023
MINNEAPOLIS, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet
September 5, 2023
MINNEAPOLIS, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today